The U.S. Food and Drug Administration (FDA) granted a supplemental approval for Opdivo (nivolumab) on July 14, 2022. This approval, designated BLA 125554 S-114, was based on new efficacy data, expanding the drug's label.
Background
Nivolumab, marketed as Opdivo, is an immune checkpoint inhibitor that targets the PD-1 receptor. It is a well-established therapeutic agent in oncology, approved for various indications across multiple cancer types. This supplemental application signifies an expansion of its approved uses, specifically related to new efficacy data that supports its benefit in an additional context.
What this means
This supplemental approval for Opdivo (nivolumab), specifically for efficacy, indicates that the FDA has reviewed and accepted new data demonstrating the drug's effectiveness in an expanded context. While the specific new indication or patient population is not detailed in the provided information, such approvals typically broaden the therapeutic options available to clinicians and patients. It allows for the use of nivolumab in a new setting where its benefits have been scientifically established, potentially improving outcomes for a wider range of patients.
Source
The information regarding this supplemental approval was obtained from the U.S. Food and Drug Administration (FDA). The approval for BLA 125554 S-114 was granted on July 14, 2022, and is publicly accessible on accessdata.fda.gov.